Many of these gene flaws - there are plenty of them, with names like BCR-ABL - are relative newcomers to medical terminology, as are a majority of the new anti-tumor drugs, still in early testing, that are aimed at them.
A medical terminology, as are a majority of the new anti-tumor drugs, still in early testing, that are aimed at them.
B medical terminology like a majority of the new anti-tumor drugs that are still in early testing, and aimed at them.
C medical terminology, as are a majority of the new anti-tumor drugs that are still in early testing, aimed at them.
D medical terminology like a majority of the new anti-tumor drugs, still in early testing, that are aimed at them.
E medical terminology, as are a majority of the new anti-tumor drugs, still in early testing, and aimed at them.
A medical terminology, as are a majority of the new anti-tumor drugs, still in early testing, that are aimed at them.
B medical terminology like a majority of the new anti-tumor drugs that are still in early testing, and aimed at them.
C medical terminology, as are a majority of the new anti-tumor drugs that are still in early testing, aimed at them.
D medical terminology like a majority of the new anti-tumor drugs, still in early testing, that are aimed at them.
E medical terminology, as are a majority of the new anti-tumor drugs, still in early testing, and aimed at them.
